• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pfizer, BioNTech Enter Vax Pact with COVAX

    FDA Approves Janssen’s CABENUVA

    AGC Biologics Appoints Boulder Site GM

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Integrated Continuous Manufacturing ICM

    CONTINUUS Awarded $69.3M DoD Grant

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy

    Coating Place Wurster Fluid Bed Process Scaling

    AbbVie Licenses ProBioGen’s GlymaxX Technology

    Improving Product Profitability
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Almac Group

    Emergent BioSolutions

    Cytovance Biologics

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Almac Group

    Cytovance Biologics

    Baxter BioPharma Solutions

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    CDMOs: Keeping up with Science & Technology

    Enhancing the development of increasingly advanced and complex drug candidates is needed to drive growth in the industry.

    CDMOs: Keeping up with Science & Technology
    Related CONTENT
    • Drug Development For Startups
    • Virtual Clinical Trials: The Future of Dermatology Studies
    • RheinCell Therapeutics Achieves GMP Certification
    • Fujifilm Diosynth Biotechnologies Begins COVID-19 Vax Production
    • Aurigene Pharmaceutical Services ltd.
    Kristin Brooks, Contract Pharma11.12.20

    The next generation of biologics present many challenges for both drug developers and their CDMO partners. Advancing molecules into clinical development and scaling up manufacturing of these increasingly complex biologics, requires advanced process development and analytical testing and highly specialized manufacturing technologies. For CDMOs it requires working faster, safer, and more efficiently, leveraging the right technologies, to drive growth in the industry.

    With recently expanded European operations and a newly updated facility in Geneva, Switzerland, JSR Life Sciences aims to increase engagement with a broader European client base. JSR will co-locate two of its affiliates - KBI Biopharma and Selexis SA – in 8,700 square meters of the “Stellar 32” facility.

    Creating new capabilities by linking the core strengths of its affiliates, KBI Biopharma’s expanded facility will enable the company to offer clinical cGMP biologics bulk drug substance manufacturing for European clients and Selexis’ new workspaces will allow the company to meet the increasing demand for its highly specialized mammalian cell line development technologies and services.

    Tim Lowery, President of JSR Life Sciences discusses the companies recently expanded European operations, some of the main challenges biopharma companies face developing and manufacturing today’s biologics, and the capabilities and technologies needed to overcome them. –KB

    Contract Pharma: What new capabilities and services will be available as a result of the company’s recently expanded European operations?

    Tim Lowery: JSR Life Sciences has best-in-class companies focused on translating our customers' ideas into actual products that are improving patients’ lives, which enables us to offer large molecule expertise to clients from target selection all the way to commercial manufacturing.

    With this particular expansion in Geneva, Switzerland, there are certain technical updates we made to KBI and Selexis’ facilities in line with JSR initiatives to innovate, modernize and digitize across all of our affiliates. For example, KBI’s expansion includes two 2,000L single-use cGMP manufacturing trains with highly advanced process development and analytical testing labs on site. The Selexis space includes, in addition to new standard cell line development suites, the two separate cell culture suites to accommodate quarantined client-specific cell lines or client-dedicated cell line spaces. The co-location of the services for these two companies provides additional benefits for our global client base and the strategic location in Switzerland provides easy access for our European clients.

    In addition, this co-location provides new capabilities for our partners by linking the core strengths of these companies. For example, the two companies have joined forces to provide industry partners working with both KBI and Selexis the “Gene to GMP™ in 9 Months” service, which can help biopharma companies achieve faster time-to-market and lower their development costs. Gene to GMP™ brings together the collective expertise of both KBI and Selexis to deliver a seamless process for rapid process development and cGMP manufacturing of protein therapeutics without sacrificing productivity or quality. For conventional mAbs and other readily expressible proteins that are amenable to a platform purification process, partners provide Gene to GMP™ with their gene sequence. Our companies can advance the development process all the way to clinical manufacturing in an accelerated fashion. This technology can also be applied to other complex and challenging constructs with similar benefits.

    CP: What are some of the main challenges Biopharma companies face developing and manufacturing today’s biologics?

    TL: Keeping up with the technology and the science in addressing patient needs is an innate challenge for the CDMO industry. Thanks to some of the best minds in the world working to help patients, treatments and drug candidates are more advanced, more complex, and those leaps forward are accelerating with the advent of new technologies. We need to keep pace with these innovations and make sure our expertise can not only accommodate, but enhance, these leaps forward. JSR Life Sciences has dealt with this by going out and recruiting some of the best in the business to make sure we are on the cutting edge of technology and life science innovations. With our affiliates Crown Bio, Selexis, KBI Biopharma, and MBL, JSR Life Sciences has positioned ourselves to access data, expertise, and resources necessary to de-risk the investments necessary for the next generation of biologics.

    CP: What capabilities and technologies are needed to overcome challenges in cell line development and manufacture?

    TL: The CHO cell line development field has evolved immensely over the last ten years, with JSR Lifesciences leading the way through the Selexis expression technology and KBI’s advanced process development and analytical capabilities. The unique genetic engineering technology platform of Selexis has led to unpreceded CHO expression productivities that have helped their partners advance more than 135 molecules into clinical development. Selexis continues to push the envelope of cell expression by continually investing in new technology development and by leading the field in new equipment adoption. KBI Biopharma is known for its strong focus on science in process and analytical development, which enables high success rates in the development of complex molecules. Their CMC expertise and cGMP manufacturing infrastructure allows for a seamless transition from clinical supply to commercial launch and beyond.

    CP: In what area(s) of JSR Life Sciences’ business do you see the most growth?

    TL: Right now, our large molecule capabilities are our foundation and I believe will continue to grow as therapeutic needs continue to be better understood, our affiliates grow, and as we are able to leverage synergies among them. In addition, I believe treatment intelligence is a burgeoning opportunity for our industry, namely biomarker and companion diagnostics. The ability to discover and advance biomarkers, which can in turn facilitate companion diagnostics, and by itself would make a treatment more likely to be successful, is a highly attractive concept for patients, providers, and payors. Building our expertise in being able to identify the right patients for the right drug is one of the major growth opportunities we’re working through.

    CP: What do you anticipate for future needs in the outsourcing space?

    TL: Working faster, safer, and more efficiently will continue to be the prevailing needs for CDMOs. Being able to identify and leverage the right technologies will be key to sustaining growth and leadership in the industry. JSR Life Science’s ‘single chain’ approach is meant to increase speed to market, driving value to our clients by providing the option to leverage world-class expertise from identifying molecules to delivering commercial batches of drug product. This also allows the technology experts – in cell lines, cGMP manufacturing like with our European facility expansion – to stay at the forefront of scientific advances and the needs of advanced therapy discovery and development. And, in turn, we can deliver these capabilities to our clients.
     


    Tim Lowery joined JSR in 1996. Throughout his tenure, he has supported JSR in several capacities including as National Sales Manager and as CEO of MBLI, a JSR Life Sciences company. Tim was instrumental in establishing JSR’s life sciences-focused business, spearheading the company’s M&A activities, and overseeing the North American life science operations. As President of JSR Life Sciences, he is responsible for the development and integration of global strategies among all the JSR Life Sciences companies, which include Crown Bioscience, KBI Biopharma, Inc., MBL and Selexis SA. He serves as board chair for Selexis and chairman of the board for KBI Biopharma.
    Related Searches
    • Bioanalytical Services
    • Drug Development
    Suggested For You
    Drug Development For Startups Drug Development For Startups
    Virtual Clinical Trials: The Future of Dermatology Studies Virtual Clinical Trials: The Future of Dermatology Studies
    RheinCell Therapeutics Achieves GMP Certification RheinCell Therapeutics Achieves GMP Certification
    Fujifilm Diosynth Biotechnologies Begins COVID-19 Vax Production Fujifilm Diosynth Biotechnologies Begins COVID-19 Vax Production
    Aurigene Pharmaceutical Services ltd. Aurigene Pharmaceutical Services ltd.
    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021 The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    AGC Biologics Manufactures Orchard Therapeutics AGC Biologics Manufactures Orchard Therapeutics' Libmeldy
    ICP-MS - Leveraging Inductively Coupled Plasma Mass Spectrometry To Its Full Potential ICP-MS - Leveraging Inductively Coupled Plasma Mass Spectrometry To Its Full Potential
    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge
    Got Floor Space? – Increase Workspace Efficiency Got Floor Space? – Increase Workspace Efficiency
    Advancing Digital Endpoints in Clinical Trials Advancing Digital Endpoints in Clinical Trials
    Life Sciences Strive for Greater Agility Life Sciences Strive for Greater Agility
    ApiJect Systems Appoints General Counsel & Chief Compliance Officer ApiJect Systems Appoints General Counsel & Chief Compliance Officer
    Navigating Uncertainty: Considerations for Life Sciences 2021 Navigating Uncertainty: Considerations for Life Sciences 2021

    Related Online Exclusives

    • Analytical Services | Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development | Fill/Finish
      A New Era of Vaccine and Biologic Drug Development

      A New Era of Vaccine and Biologic Drug Development

      As a result of COVID-19, unprecedented investments in vaccines, diagnostics, and treatments have had a tremendous impact on the Biotechnology industry.
      Kristin Brooks, Managing Editor 01.12.21

    • Clinical Trials | Drug Development | Information Technology
      Advancing Digital Endpoints in Clinical Trials

      Advancing Digital Endpoints in Clinical Trials

      An end-to-end approach to managing wearable devices through clinical development.
      Kristin Brooks, Contract Pharma 12.14.20

    • Drug Delivery | Drug Development
      Inhaled Drug Delivery Technology Trends

      Inhaled Drug Delivery Technology Trends

      The success of new inhaled medicines relies on the correct combination of formulation and device technology.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 11.24.20


    • Clinical Trials | Drug Development | Preclinical Outsourcing
      Accelerating R&D Trends

      Accelerating R&D Trends

      The pandemic has propelled lingering trends into the forefront and increasingly complex molecules and biologics have drug developers outsourcing more.
      Kristin Brooks, Contract Pharma 10.20.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Contract Pharma 08.25.20

    • Drug Development | Information Technology
      Trade Secret Litigation: Vulnerabilities Within Pharma Amid Hacking Efforts

      Trade Secret Litigation: Vulnerabilities Within Pharma Amid Hacking Efforts

      Theft of IP belonging to companies developing biologics and other drugs, including COVID-19 treatments and vaccines, poses a threat to innovation.
      Kristin Brooks, Contract Pharma 08.19.20


    • Drug Development | Industry News
      Top Companies Report: Biogen

      Top Companies Report: Biogen

      Expands pipeline of disease-modifying therapies for Alzheimer’s and Parkinson’s, adds gene therapies focused on AAV treatments, bolsters biosimilars portfolio.
      Kristin Brooks, Contract Pharma 07.10.20

    • Analytical Services | Biologics, Proteins, Vaccines | Drug Development | Drug Discovery | Laboratory Testing
      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      Responding to demand for challenging assays and custom solutions required for complex molecules, biologics, vaccines and other innovative therapies.
      Kristin Brooks, Contract Pharma 06.22.20

    • Drug Development | Information Technology
      Advancing AI Initiatives in R&D

      Advancing AI Initiatives in R&D

      Richard Lee of ACD/Labs discusses the possibilities of using AI in R&D, and what this outlook means for IT leaders at pharmaceutical organizations.
      Kristin Brooks, Contract Pharma 06.11.20


    • Clinical Trials | CRO News | Drug Development | Information Technology | R&D
      CRO Industry Update

      CRO Industry Update

      Serge Bodart of IDDI provides insight on the pharma and biopharma trends impacting CROs, outsourcing in today’s market, and advances in clinical research.
      Kristin Brooks, Contract Pharma 04.27.20

    • Drug Development | R&D
      COVID-19 and the Importance of Combating Antimicrobial Resistance

      COVID-19 and the Importance of Combating Antimicrobial Resistance

      Dr. Frank of Working to Fight AMR discusses the global COVID-19 pandemic and the critical need to address the public health crisis of Antimicrobial Resistance
      Kristin Brooks, Contract Pharma 04.13.20

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Clinical Trials | Drug Development | Scale-up/Technology Transfer
      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
      Kristin Brooks, Contract Pharma 04.03.20


    • Biologics, Proteins, Vaccines | Clinical Trials | Drug Development
      COVID-19 Vaccine Response

      COVID-19 Vaccine Response

      ICON execs discuss developments in vaccine research efforts and key challenges of delivering a coronavirus vaccine
      Kristin Brooks, Contract Pharma 04.01.20

    • cGMP Manufacture | Drug Development | Logistics | Supply Chain
      COVID-19: Business Update

      COVID-19: Business Update

      Thermo Fisher Scientific provides perspective on the COVID-19 pandemic and how the company is working to help minimize disruptions
      Kristin Brooks, Contract Pharma 03.30.20

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Clinical Trial Materials | Drug Development
      Newsmakers: Thermo Fisher Scientific

      Newsmakers: Thermo Fisher Scientific

      Leon Wyszkowski discusses the company’s recent investments, the challenges biopharma companies face, and future needs in the outsourcing space
      03.16.20

    Trending
    • Integrated Continuous Manufacturing ICM
    • AbbVie Licenses ProBioGen’s GlymaxX Technology
    • CONTINUUS Awarded $69.3M DoD Grant
    Breaking News
    • Pfizer, BioNTech Enter Vax Pact with COVAX
    • FDA Approves Janssen’s CABENUVA
    • AGC Biologics Appoints Boulder Site GM
    • Lilly Completes $1B Acquisition of Prevail
    • Top BioPharma Form Accumulus Synergy
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    LINE-X Launches Dealer Program with International Truck
    PPG Reports Q4, Full-year 2020 Financial Results
    BASF Begins Implementing Ralignment of Global Business Services Unit
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex Companies CEO Steps Down
    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    Endoscopic Hemostasis Devices Market Valued at $730 Million
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pfizer, BioNTech Enter Vax Pact with COVAX
    FDA Approves Janssen’s CABENUVA
    AGC Biologics Appoints Boulder Site GM
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty Appoints Chief Procurement Officer
    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Happi

    Latest Breaking News From Happi

    Carol’s Daughter Adds New Hair Products
    Moroccan Gold Series Launches NuDo Shampoo
    Youbody Debuts Waterless Body Wash
    Ink World

    Latest Breaking News From Ink World

    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    AR Packaging Acquiring Firstan Holdings Ltd
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Gallus planning virtual event for March
    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Lemu Group Engineers Mask-Making Machine
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Cretex Companies CEO Steps Down
    Conformis Enters Development & Supply Agreement with SITES Medical
    Sectra, RSA Biomedical Sign Distribution Agreement for Implant Stability Tool
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Ambiq Wins IoT Semiconductor Company of the Year Award
    Ynvisible Names Michael Robinson CEO, Jani-Mikael Kuusisto SVP Ventures

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login